Frequently Asked Questions (FAQ)
The information provided below does not take into account your individual investment objectives, financial situation and needs. The information is of a general nature and is not financial product advice and should not be relied upon as the sole basis for any investment decision. As a holder of Shares (Shareholder), you should consult your financial, legal, tax or other professional advisor in relation to the information contained below and how you should act with respect to your Shares.
Is QBiotics planning to undertake an Initial Public Offering (IPO)?
On 25 March 2025, QBiotics announced that it has appointed Jefferies (Australia) Pty Ltd (Jefferies) and Bell Potter Securities Limited (Bell Potter) as Joint Lead Managers (JLMs) to advise upon and assist QBiotics with a potential initial public offering (IPO) on the Australian Securities Exchange (ASX) this calendar year.
A full copy of the announcement is available here.
The Company remains committed to keeping shareholders informed as developments arise.
Shareholders should note the appointment of JLMs (or any other professional advisors) does not guarantee that an IPO will proceed. Any decision including the timing of the IPO will be made in due course, subject to market conditions and other relevant factors.
When does QBiotics plan to undertake an Initial Public Offering?
The Directors are hopeful that the IPO of the Company could be completed in calendar 2025. It should be noted, however, that the timing of any IPO is impacted by numerous issues including matters that are out of their control, including global and local economic conditions.
What is the price / value at which the Company's shares are going to list?
The Directors will be taking advice from the Joint Lead Managers (JLMs) on the matter of issue price of the shares in any IPO. No decision regarding the issue price has been made at this stage.
Why would you choose to undertake an IPO in the timeframe described above?
The Board believes that on the balance of the following factors, the Company is in a strong position to pursue an IPO:
- Strong leadership in place across Board and Management to execute on the next stage of growth
- Compelling clinical data building for tigilanol tiglate in a range of tumour types and ongoing clinical trials to further validate the drug
- Pathway to registration for tigilanol tiglate in soft tissue sarcomas (STS), supported by Orphan Drug status, with compelling phase II data and an extension study opening
- Second promising asset, wound healing drug candidate, EBC-1013, in clinic and a preclinical pipeline behind it
For more information on the Company’s current activities, please visit our announcements page.
Can I buy / sell QBiotics shares?
With the exception of our share trading policy which only applies to our directors and employees, the Company does not place any restrictions on shareholders buying or selling shares independently including via independent facilities where investors can buy or sell shares.
QBiotics is not responsible or liable for any loss that may arise from shareholders’ trading in the secondary market.
When will you be in a position to tell us more about the IPO?
The Company will keep the shareholders updated on any developments to the IPO proposal in keeping with its disclosure obligations.